Moberg Pharma ABFRA:MB8 -2.95%59 PB Ratio is 0.60 as of Jun. 26, 2026, which is 29% below its 10-year median of 0.84. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.09. The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Moberg Pharma AB ranks better than 87.09% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Moberg Pharma AB's share price is €0.789. Moberg Pharma AB's Book Value per Share for the quarter that ended in Mar. 2026 was €1.31. Hence, Moberg Pharma AB's PB Ratio of today is 0.60.
The historical rank and industry rank for Moberg Pharma AB's PB Ratio or its related term are showing as below:
FRA:MB8'
s PB Ratio Range Over the Past 10 Years
Min: 0.12 Med: 0.84 Max: 2.35
Current: 0.66
During the past 13 years, Moberg Pharma AB's highest PB Ratio was 2.35. The lowest was 0.12. And the median was 0.84.
FRA:MB8's PB Ratio is ranked better than 87.09% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs FRA:MB8: 0.66
During the past 12 months, Moberg Pharma AB's average Book Value Per Share Growth Rate was -3.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -42.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -17.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Moberg Pharma AB was 431.90% per year. The lowest was -51.50% per year. And the median was 13.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Moberg Pharma AB PB Ratio Related Terms
Moberg Pharma AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Moberg Pharma AB (FRA:MB8) has a PB Ratio of 0.60 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Moberg Pharma AB and its competitors. This is 29% below median its historical median of 0.84. Over the past decade, Moberg Pharma AB's PB Ratio has ranged from 0.12 to 2.35. According to the industry distribution chart, Moberg Pharma AB ranks #119 out of 922 companies in the Drug Manufacturers industry, placing it in the top 12.9%.
Is Moberg Pharma AB's PB Ratio too high?
Moberg Pharma AB's current PB Ratio of 0.60 is 29% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 2.35. The Drug Manufacturers industry median PB Ratio is 1.83. Moberg Pharma AB's value of 0.60 is 67.1% below this industry median. Based on the distribution chart, Moberg Pharma AB ranks #119 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #119 out of 922 companies for PB Ratio. This places Moberg Pharma AB in the top 13% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.83. Moberg Pharma AB's value of 0.60 is 67.1% below this benchmark. Historically, Moberg Pharma AB's own PB Ratio has ranged from 0.12 to 2.35 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 1.83, Moberg Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current PB Ratio of 0.60 is 67.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current PB Ratio is 0.60, which is 29% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current PB Ratio of 0.60. The stock's GF Value™ is €1.09, compared to a current price of €0.79 — trading 27.6% below its estimated fair value. The current PB Ratio is 0.60, which is 29% below median its 10-year median of 0.84 and 67.1% below the Drug Manufacturers industry median of 1.83. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current PB Ratio is 0.60 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of €0.79 is trading 27.6% below its estimated GF Value™ of €1.09.
Key valuation signals for FRA:MB8:
PB Ratio: 0.60 (29% below median its 10-year median of 0.84)
GF Value™: €1.09 vs. price of €0.79 (27.6% below fair value)
Industry Position: 67.1% below the Drug Manufacturers median (#119 of 922)
No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score
Get the complete analysis for FRA:MB8
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MB8 has been successfully added to your 
